Clinical Pharmacology Section, Internal Medicine Service, Hospital Italiano de Buenos Aires, Tte. Gral. Juan Domingo Perón 4190 C1199, Buenos Aires, Argentina.
Transfusional Medicine Department, Hospital Italiano de Buenos Aires, Tte. Gral. Juan Domingo Perón 4190, C1199 Buenos Aires, Argentina.
Transfus Apher Sci. 2023 Dec;62(6):103785. doi: 10.1016/j.transci.2023.103785. Epub 2023 Aug 12.
Convalescent plasma (CP) became a prominent treatment in the early stages of the SARS-CoV-2 pandemic. In Argentina, a randomized clinical trial was executed to compare the use of CP in inpatients with severe COVID-19 pneumonia versus placebo. No differences in clinical outcomes or overall mortality between groups were observed. We conducted a cohort study in outpatients enrolled in the trial to describe long-term antibody titer variations between CP and placebo recipients.
Patients' total SARS-CoV-2 IgG antibodies against spike protein were collected 3, 6 and 12 months after hospital discharge from August 2020 to December 2021. In addition, reinfections, deaths and vaccination status were retrieved. Statistical analysis was performed using antibody geometric mean titers (GMT). All estimations were made considering the date of the trial infusion (placebo or CP) as time 0.
From the 93 patients included in the follow-up, 64 had received CP and 29 placebo. We excluded all 12-month measurements because they were collected after the patients' vaccination date. At 90 days post-infusion, patients had an antibody GMT of 8.1 (IQR 7.4-8.1) in the CP group and 8.8 (IQR 8.1-9.1) in the placebo group. At 180 days, both groups had a GMT of 8.1 (IQR 7.4-8.1). No statistical differences in GMT were found between CP and placebo groups at 90 days (p = 0.12) and 180 days (p = 0.25). No patients registered a new COVID-19 infection; one died in the CP group from an ischemic stroke.
No differences were observed in long-term antibody titers in unvaccinated patients that received CP or placebo after severe COVID-19 pneumonia.
恢复期血浆（CP）在 SARS-CoV-2 大流行的早期成为一种重要的治疗方法。在阿根廷，进行了一项随机临床试验，比较了 CP 在重症 COVID-19 肺炎住院患者中的应用与安慰剂的效果。两组之间在临床结局或总体死亡率方面没有观察到差异。我们对参与该试验的门诊患者进行了队列研究，以描述 CP 和安慰剂组患者在出院后 3、6 和 12 个月之间的长期抗体滴度变化。
从 2020 年 8 月至 2021 年 12 月，收集了出院后 3、6 和 12 个月患者针对刺突蛋白的总 SARS-CoV-2 IgG 抗体。此外，还检索了再感染、死亡和疫苗接种情况。使用抗体几何平均滴度（GMT）进行统计分析。所有估计均考虑了试验输注（安慰剂或 CP）的日期作为时间 0。
在纳入随访的 93 名患者中，64 名接受了 CP，29 名接受了安慰剂。我们排除了所有 12 个月的测量值，因为它们是在患者接种疫苗日期之后采集的。在输注后 90 天，CP 组患者的抗体 GMT 为 8.1（IQR 7.4-8.1），安慰剂组为 8.8（IQR 8.1-9.1）。在 180 天，两组的 GMT 均为 8.1（IQR 7.4-8.1）。CP 组和安慰剂组在 90 天（p=0.12）和 180 天（p=0.25）时的 GMT 无统计学差异。没有患者登记新的 COVID-19 感染；CP 组有一名患者因缺血性中风死亡。
在未接种疫苗的重症 COVID-19 肺炎患者中，接受 CP 或安慰剂后，长期抗体滴度没有差异。
